论文部分内容阅读
★Takeda制药公司重新提交了两项糖尿病治疗的新药申请(NDAs)Takeda制药公司向FDA重新提交了alogliptin benzoate和固定剂量单片alogliptin/pioglitazone联合治疗的两份新药申请(NDAs)。FDA将在6个月内审查这份重新提交的申请。Alogliptin是一种正在美国进行开发的选择性二肽基肽酶4(DPP-4)抑制剂,用于辅助饮食和锻炼治疗2型糖尿病。本品
Takeda Pharmaceuticals Resubmits Two New Drug Applications for Diabetes Treatment (NDAs) Takeda Pharmaceuticals resubmitted two new drug applications (NDAs) to the FDA for the combination of alogliptin benzoate and a fixed-dose monolithic alogliptin / pioglitazone. FDA will review the resubmitted application within six months. Alogliptin is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor that is being developed in the United States to aid in diet and exercise to treat type 2 diabetes. This product